NEUROENDOCRINE CARCINOMAS
Clinical trials for NEUROENDOCRINE CARCINOMAS explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE CARCINOMAS trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE CARCINOMAS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug target for rare cancers enters human testing
Disease control Recruiting nowThis early-phase trial tests a new drug called ADCT-701 in adults with rare cancers of the digestive tract, pancreas, lungs, or adrenal glands. The main goal is to find the safest dose and see if the drug can shrink tumors. Participants receive the drug through an IV every 3 week…
Matched conditions: NEUROENDOCRINE CARCINOMAS
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:27 UTC
-
New drug IDE849 targets tough lung cancers in early trial
Disease control Recruiting nowThis study tests a new drug called IDE849 in people with cancers that have a specific marker called DLL3, including small cell lung cancer and other solid tumors. The trial has two parts: first to check safety and find the right dose, then to see if the drug shrinks tumors or slo…
Matched conditions: NEUROENDOCRINE CARCINOMAS
Phase: PHASE1, PHASE2 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated May 22, 2026 13:50 UTC